VectorY Raises €74.5 Million to Push ALS Antibody Into Late Readout

VectorY Therapeutics has raised €74.5 million — roughly $83.5 million — to push its lead vectorized antibody, VTx-002, through the final readout of the PIONEER-ALS Phase 1/2 study and to fund a broader neurodegenerative pipeline.

The round, announced by the Amsterdam-based biotech, brings in three new investors: Angelini Ventures, Invest-NL and the European Investment Bank. They join a heavyweight returning syndicate of Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures, Eli Lilly and Company, and the ALS Investment Fund.

The lead asset matters because of its target. VTx-002 goes after pathological TDP-43, a protein that aggregates abnormally in up to 97% of people with amyotrophic lateral sclerosis. VectorY's delivery approach — a vector carrying the antibody construct — is designed to produce sustained antibody expression inside the central nervous system. The therapy remains investigational and carries no regulatory approval.

What does the money actually fund?

Two things, per the company: clinical execution on VTx-002 and pipeline expansion around the platform.

• VTx-002 in ALS: financing carries the program through clinical milestones, including the final readout of PIONEER-ALS.
• VTx-003 in Huntington's disease: the next program in line for funding.
• Platform buildout: combining antibody engineering with vector-based delivery and manufacturing.

CEO Jim Scibetta framed the round as a vote of confidence with a delivery attached: "This financing reflects strong confidence in our team, our platform and the potential of our pipeline. It will support the advancement of VTx-002 through important clinical milestones, including the final readout of PIONEER-ALS, while enabling us to leverage our vectorized antibody platform to expand its application in multiple neurodegenerative diseases across our pipeline."

He didn't soften the backdrop. "Neurodegenerative diseases represent some of the most complex challenges in medicine, and patients and families urgently need new treatment options," Scibetta said.

What is PIONEER-ALS testing?

PIONEER-ALS is a global, multicenter, open-label, dose-escalation study testing two dose levels in adults with ALS. Sites sit across the United States, Europe and the United Kingdom.

The study measures safety, tolerability, pharmacokinetics and exploratory efficacy. The readout battery runs deep:

• Neurofilament light chain
• TDP-43 pathway-related biomarkers
• Functional assessments
• Respiratory measures
• Muscle strength
• Survival

In September 2026, VectorY expanded the trial from 12 to 36 participants. Enrollment is ongoing.

That tripling of the cohort is the detail investors are watching. Wouter Joustra, General Partner at Forbion — the firm leading the returning backers — tied the cheque directly to it: "Its progress with VTx-002, including the expansion of the PIONEER-ALS study, is an important step in evaluating the program's potential. This financing will help the company advance that work while developing additional programs, including VTx-003 for Huntington's disease."

Joustra also called VectorY's approach "a compelling approach to one of the most challenging areas of medicine" and said Forbion is pleased to keep backing the company as it "translates its platform into potential pioneering treatment options for people living with neurodegenerative diseases."

How far does the platform stretch?

Beyond ALS and Huntington's, VectorY's pipeline reaches into two of the largest neurodegenerative markets:

• VTx-004: targeting TDP-43 in frontotemporal dementia
• VTx-005: targeting phosphorylated tau in Alzheimer's disease

Both programs rest on the same architecture: an engineered antibody delivered by vector, built on in-house manufacturing capability. The financing supports evaluation of the lead program and the broader development of that platform.

The bet, in plain terms: €74.5 million buys VectorY the PIONEER-ALS readout and a shot at proving one delivery engine works across four diseases.